Nexalin Technology (NXL) Return on Capital Employed (2022 - 2026)
Nexalin Technology's (NXL) quarterly Return on Capital Employed came in at 253.22% in Q1 2026, up 3781.0% year-on-year from 6.52% in Q1 2025, and down 20.51% quarter-over-quarter from 210.12% in Q4 2025.
Nexalin Technology (NXL) Return on Capital Employed (2022 - 2026) Analysis & Trends
Nexalin Technology's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 253.22% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 3781.0% year-over-year to 253.22% in Q1 2026; TTM through Mar 2026 was 253.22%, a 3781.0% increase from a year earlier, with the FY2025 full-year figure at 236.92%, down 753.0% from the prior year.
- Return on Capital Employed eased to 253.22% in Q1 2026 per NXL's latest filing, from 210.12% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.84% in Q4 2022 and bottomed at 322.71% in Q2 2024.
- The 5-year median for Return on Capital Employed is 197.0% (2024), against an average of 178.13%.
- Across the five-year window, Return on Capital Employed tumbled 26163 bps in 2024 and jumped 10448 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 30.84% in 2022, then tumbled by 412 bps to 157.9% in 2023, then fell by 17 bps to 184.93% in 2024, then slipped by 14 bps to 210.12% in 2025, then declined by 21 bps to 253.22% in 2026.
- Per Business Quant, the three latest NXL Return on Capital Employed figures stand at 253.22% (Q1 2026), 210.12% (Q4 2025), and 161.33% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | -253.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -253.22% |
| Dec 31, 2025 | -210.12% |
| Sep 30, 2025 | -161.33% |
| Jun 30, 2025 | -218.23% |
| Mar 31, 2025 | -291.03% |
| Dec 31, 2024 | -184.93% |
| Sep 30, 2024 | -209.07% |
| Jun 30, 2024 | -322.71% |
| Mar 31, 2024 | -219.77% |
| Dec 31, 2023 | -157.90% |
| Sep 30, 2023 | -132.81% |
| Jun 30, 2023 | -61.07% |
| Mar 31, 2023 | -40.78% |
| Dec 31, 2022 | -30.84% |